SubsidieMeestersLaser bioprinting device and in vivo applications
PhosPrint's D-LIB platform uses a laser bioprinter for precise in-vivo tissue printing, aiming to enhance surgical outcomes in bladder cancer patients through real-time tissue engineering.
Projectdetails
Introduction
PhosPrint's D-LIB platform technology is based on a compact and automated laser bioprinter and protocols for high-speed and high-precision in-vivo printing of tissues with autologous human body characteristics.
Technology Overview
The bioprinter relies on the Laser Induced Forward Transfer (LIFT) technique to accomplish highly accurate and cost-effective printing of tissues.
System Components
The bioprinter system is associated with protocols for:
- Cell isolation from autologous biopsies
- Cell expansion in-vitro
- Cell printing in-vivo
Innovative Approach
This is a truly new approach that allows for real-time tissue engineering/repair in complex medical conditions.
Market Application
D-LIB capabilities will enable the introduction of a laser bioprinting technology in surgery operations, starting with enterocystoplasty/augmentation in cystectomy bladder cancer patients as the selected go-to-market application.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.000.560 |
| Totale projectbegroting | € 2.857.946 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 31-10-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- PHOSPRINT IDIOTIKI KEFALAIOUXIKIETAIREIApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Development of an enhanced laser beam technology based on a new optical system for industrial laser processing applications.InPhocal aims to enhance laser marking systems by integrating a miniaturized optical device for improved resolution, speed, and versatility, while reducing environmental impact. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Development of an enhanced laser beam technology based on a new optical system for industrial laser processing applications.
InPhocal aims to enhance laser marking systems by integrating a miniaturized optical device for improved resolution, speed, and versatility, while reducing environmental impact.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Better Bioprinting by Light-sheet LithographyB-BRIGHTER aims to develop a novel high-speed bioprinting technology for creating complex engineered tissues, enhancing drug testing and therapeutic applications while fostering healthcare innovation. | EIC Transition | € 2.093.331 | 2022 | Details |
A novel support material for 3D bioprinting and post-printing tissue growth: Print and GrowThe "Print and Grow" project aims to enhance 3D bioprinting stability and viability of tissue constructs through a novel microgel support, optimizing for diverse tissue types and in vivo applications. | ERC Proof of... | € 150.000 | 2022 | Details |
Surgical optogenetic bioprinting of engineered cardiac muscleLIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart. | ERC Starting... | € 1.499.705 | 2023 | Details |
PRInted Symbiotic Materials as a dynamic platform for Living Tissues productionPRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications. | EIC Pathfinder | € 2.805.403 | 2022 | Details |
Human based bioinks to engineer physiologically relevant tissuesHumanINK aims to validate human-based bioinks for 3D bioprinting, creating advanced cell culture environments to enhance drug development and reduce reliance on animal testing. | ERC Proof of... | € 150.000 | 2022 | Details |
Better Bioprinting by Light-sheet Lithography
B-BRIGHTER aims to develop a novel high-speed bioprinting technology for creating complex engineered tissues, enhancing drug testing and therapeutic applications while fostering healthcare innovation.
A novel support material for 3D bioprinting and post-printing tissue growth: Print and Grow
The "Print and Grow" project aims to enhance 3D bioprinting stability and viability of tissue constructs through a novel microgel support, optimizing for diverse tissue types and in vivo applications.
Surgical optogenetic bioprinting of engineered cardiac muscle
LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.
PRInted Symbiotic Materials as a dynamic platform for Living Tissues production
PRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications.
Human based bioinks to engineer physiologically relevant tissues
HumanINK aims to validate human-based bioinks for 3D bioprinting, creating advanced cell culture environments to enhance drug development and reduce reliance on animal testing.